The examining
board of the 2004 Reward
of the Geneva Industry
announces that: The Geneva
Industry Prize has been
awarded on Thursday 11th
November 2004, to the
Company OM PHARMA
This choice has been based
on the facts that:
- The company is located
in Geneva for more than
60 years
- Thanks to its dedication,
its research and its harmonious
development during the
years, OM PHARMA contributes
to the reputation of our
city
- Its strategy built on
independence, self-financing
as well as research and
development, gives rise
to important repercussions
not only in the pharmaceutical
sector, but also on the
global economy of Geneva
- As a niche company,
OM PHARMA is a leader
in its domain.
 |
New Uro-Vaxom®
study
In this 12-month double-blind,
randomized, placebo-controlled
trial * , 453 women suffering
from recurrent urinary
tract infections (UTI)
were treated for 3 months
with one capsule daily
of the lyophilized immunostimulating
Escherichia coli extract
Uro-Vaxom® (n=231)
or placebo (n=222), then
with three 10-day boosters
in months 7 to 9 and observed
for a further 3 months.
Uro-Vaxom® achieved
a significant 34% reduction
in the mean rate of UTI
episodes with respect
to placebo (0.84 vs 1.28;
p=0.0026). Of particular
interest was the contributing
effect to the treatment’s
efficacy of the 3 boosters
given in the second half
of the trial as the reduction
in the UTI rate was much
greater during that period
(- 43%).
As regards the secondary
parameters, it reduced
the total duration of
UTI, the severity of symptoms
and the need for concomitant
antibiotics and other
urinary anti-infectives.
The safety profile was
good and consistent with
that previously reported.
These results were also
presented at the last
Congress of the European
Association of Urology
(Istanbul, March 16th-19th,
2005) by Pr CC Schulman
(Department of Urology,
Erasmus Hospital, Brussels)
where they attracted great
interest as this product
constitutes a valuable
asset not only for decreasing
UTI recurrences, but also
for reducing antibiotic
prescriptions and their
accompanying risk of bacterial
resistance.
Furthermore this study
received positive comments
in Nature Clinical Practice
of Urology (2:207, 2005)
in : “Immunotherapy
reduces incidence of urinary
tract infections in women”
as well as on the specialised
US-based web site www.UroToday.com
in : “The use of
E. coli extract (OM-89)
is safe and effective
in reducing recurrent
urinary tract infections
in women” (Dr ML
Moy, 22.04.2005).
* HW Bauer, S Alloussi,
G Egger, HM Bluemlein,
G Cozma, CC Schulman.
A long-term multicenter,
double-blind study of
an Escherichia coli extract
(OM-89) in female patients
with recurrent urinary
tract infections. European
Urology 47:542-8, 2005
< Back
Top of the page
